MedTrace Logo

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.

The names of the study drugs involved in this study are:

* DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein)
* Paclitaxel (a type of antimicrotubule agent)

Conditions

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Recurrent Ovary Cancer
  • Recurrent Platinum-Resistant Ovarian Carcinoma

Interventions

DRUG

DT2216

A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.

DRUG

Paclitaxel

An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Dialectic Therapeutics, Inc

    collaborator INDUSTRY

  • American Society of Clinical Oncology

    collaborator OTHER

  • Elizabeth Stover, MD, PhD

    lead OTHER

Principal Investigators

  • Elizabeth Stover, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-12-30
Completion
2027-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964009 on ClinicalTrials.gov